Development of allo-activated macrophage suppression method aiming at efficiency of Intravenous Immunoglobulin therapy

2016 Fiscal Year Final Research Report

• Project/Area Number: 26462466
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Osaka Medical College
• Principal Investigator: Nomi Hayahito 大阪医科大学, 医学部, 准教授 (80418938)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: アロ活性化マクロファージ / 免疫グロブリン大量療法 / 同種異型移植 / 免疫抑制剤

Outline of Final Research Achievements

Meth A fibro-sarcoma cells transplanted into allogeneic C57Bl/6 mice peritoneal cavities proliferate initially, and then Meth A are rejected out from the mice. The secondary transplantations of Meth A were caused antibody related acute rejections in C57Bl/6 mice. We collected the peritoneal exudate cells (PEC) from these secondary transplantations (S-PEC). And we investigated cytotoxic activity of S-PEC in complement immobilized conditions with 51Cr releasing assays.
We isolated each fractions of S-PEC with FACS cell-sorter, and confirmed the highest allogeneic cytotoxicity was seen in allograft induced macrophages (AIM) fractions. And, we found the activities of AIM were attenuated by massive nonspecific IgG antibodies, in vitro. The removal of AIM in S-PEC also attenuates the cytotoxic activity of S-PEC. It is presumed IVIG acts on cytotoxic activity of AIM. There is a necessity to evaluate the inhibitory effect of IVIG on AIM without compromising complement.

Free Research Field

泌尿器科学、腎移植